Clofazimine, previously used in the treatment of leprosy, is now used for treatment of Mycobacterium avium complex infection in patients with acquired immune deficiency syndrome, dermatologic disorders, and graft-versus-host disease. An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease. Clofazimine enteropathy caused by crystal deposition can be life-threatening.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1067/mpd.2001.111327 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clofazimine enteropathy: a case of pigmentation of the whole small intestine caused by clofazimine.
Endoscopy
December 2024
Department of Gastroenterology, Mianyang Central Hospital, Mianyang, China.
Why do we use 100 mg of clofazimine in TB and NTM treatment?
J Antimicrob Chemother
April 2024
Department of Medical Microbiology (777), Radboudumc Community for Infectious Diseases, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.
Current tuberculosis and non-tuberculous mycobacterial disease guidelines recommend the use of clofazimine in a 100 mg once-daily dose. The rationale behind this exact dose is not provided. I performed a literature review to determine the reasoning behind the current dosing regimen.
View Article and Find Full Text PDFClofazimine-associated enteropathy.
Gastrointest Endosc
June 2024
Department of Gastroenterology, Peking University First Hospital, Beijing, China.
Clofazimine pharmacokinetics in HIV-infected adults with diarrhea: Implications of diarrheal disease on absorption of orally administered therapeutics.
CPT Pharmacometrics Syst Pharmacol
March 2024
Department of Pharmaceutics, University of Washington, Seattle, Washington, USA.
Article Synopsis
- Oral drug absorption, particularly of clofazimine, can be significantly affected by diarrhea associated with infections like cryptosporidiosis in HIV-infected adults.
- A population pharmacokinetic model using data from a study of 23 participants revealed that severe diarrhea can reduce clofazimine bioavailability by more than sixfold.
- Understanding these effects is crucial for optimizing dosing regimens to improve treatment outcomes for patients experiencing gastrointestinal issues.
Examination of ELISA against PCR for assessing treatment efficacy against Cryptosporidium in a clinical trial context.
PLoS One
September 2023
University of Virginia, Charlottesville, Virginia, United States of America.
Article Synopsis
- Cryptosporidium is a gut pathogen that particularly affects people with weakened immune systems, such as those with HIV, and the CRYPTOFAZ trial in Malawi tested clofazimine's effectiveness for treating this infection.
- The study used various diagnostic methods, including qPCR and ELISA, to examine 586 individuals and monitor those who were part of the trial for pathogen shedding and other co-infections.
- The findings revealed that while qPCR was more sensitive for detecting Cryptosporidium, ELISA had more variable results; additionally, a new Cryptosporidium species was found, and enterotoxigenic E. coli was also linked to diarrhea in some participants.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!